Benzinga's Top #PreMarket Losers

Infinity Pharmaceuticals, Inc. INFI shares fell 12.52% to $14.26 in pre-market trading. Infinity Pharmaceuticals' Phase 2 study Of Duvelisib with background methotrexate in patients with moderate-to-severe rheumatoid arthritis did not meet primary endpoint. Insulet CorporationPODD shares dropped 7.93% to $41.00 in pre-market trading after the company lowered its FY2014 sales guidance. GW Pharmaceuticals PLC- ADRGWPH fell 6.44% to $66.48 in pre-market trading after the company issued an update on Epidilex. Sativex didn't meet primary endpoint in first trial. AmTrust Financial Services, Inc. AFSI shares dropped 4.57% to $51.53 in pre-market trading after the company announced the pricing of a three million share offering. Alexion Pharmaceuticals, Inc. ALXN shares declined 4.22% to $180.00 in pre-market trading after the company provided update on Phase 2 clinical trial with Eculizumab.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMovers & ShakersPre-Market OutlookMarketsTop Losers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!